Reporting from: – Annual Meeting of the American Society of Hematology, December 4-7, 2004, San Diego – Chemotherapy Foundation Symposium, November 10-13 2004, New York – European So
Reporting from:
– Annual Meeting of the American Society of Hematology, December 4-7, 2004, San Diego
– Chemotherapy Foundation Symposium, November 10-13 2004, New York
– European Society for Medical Oncology Congress, October 29-November 2, 2004, Vienna
– Journal of Clinical Oncology
– New England Journal of Medicine
In this edition:
At the ASH conference in San Diego, Owen O’Connor described his investigation involving heavily pretreated patients with mantle cell lymphoma whose disease responded to bortezomib. George Canellos discussed the clinical implications.
Rituximab-CHOP combination therapy markedly improved outcomes for low-risk, younger patients with diffuse large B-cell lymphoma, according to study results announced by Michael Pfreundschuh.
The oral 5-FU pro-drug capecitabine has performed as well as intravenous therapy, according to Chris Twelves, who presented findings to the Chemotherapy Foundation in New York.
The older drug hydroxyurea was just as effective and caused fewer complications than its molecularly targeted modern replacement, anagrelide, for treating patients with essential thrombocythemia, according to Tony Green,who spoke in San Diego.
Related Episodes
Charles E Geyer MD; ESMO 2025: Antibody Drug Conjugate T-DXd Brings Longer Cancer-Free Survival for Patients with HER2-Positive Early Breast Cancer and Residual Invasive Disease
Charles E Geyer MD, at ESMO 2025, discusses DESTINY-Breast05 results, revealing trastuzumab deruxtecan (T-DXd) significantly improves disease-free survival for HER2-positive early breast cancer patients with residual invasive disease after neoadjuvant therapy. T-DXd outperformed trastuzumab emtansin
Li Zhang MD; ESMO 2025: Patients with EGFR-mutated Lung Cancer Progressing After Tyrosine Kinase Therapy Live Longer with Sacituzumab Tirumotecan Therapy
Antibody Drug Conjugate Prolongs Life in NSCLC refractory to EGFR TKI Therapy
Xiuning Le MD PhD; ESMO 2025: Sevabertinib Success for Patients with HER2-Mutated Non-Small Cell Lung Cancer in SOHO-01 Study
A new anti cancer drug sevabertinib, that targets mutated HER2, has proved effective in the SOHO-01 study among patients wiith HER2 mutated non small cell lung cancer. It has now been reported in the